Citius Oncology/$CTOR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Citius Oncology
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
- Ticker
- $CTOR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Cranford, United States
Citius Oncology Metrics
BasicAdvanced
$59M
-
-$0.49
3.53
-
Price and volume
Market cap
$59M
Beta
3.53
52-week high
$1.83
52-week low
$0.49
Average daily volume
135K
Financial strength
Current ratio
0.726
Quick ratio
0.293
Long term debt to equity
0.253
Total debt to equity
0.253
Interest coverage (TTM)
-129.05%
Profitability
Gross margin (TTM)
74.82%
Net profit margin (TTM)
-648.32%
Operating margin (TTM)
-668.15%
Effective tax rate (TTM)
-0.41%
Management effectiveness
Return on assets (TTM)
-29.12%
Return on equity (TTM)
-126.58%
Valuation
Price to revenue (TTM)
7.295
Price to book
1.45
Price to tangible book (TTM)
1.45
Price to free cash flow (TTM)
-1.613
Free cash flow yield (TTM)
-62.00%
Free cash flow per share (TTM)
-0.344
Growth
Earnings per share change (TTM)
31.90%
3-year earnings per share growth (CAGR)
27.45%
What the Analysts think about Citius Oncology
Analyst ratings (Buy, Hold, Sell) for Citius Oncology stock.
Analyst projections of the future price of Citius Oncology stock.
Citius Oncology Financial Performance
Revenues and expenses
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.